Dermatology

An analysis of the NIH's All of Us program finds no increased ILD risk with methotrexate in dermatomyositis.

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

A new study found a 2-week mindfulness-based intervention for patients with psoriasis does not improve skin status—it only helps the mind.

This observational cohort study looked at the link between obesity and eczema, highlighting regional differences in the skin disease and obesity’s interdependence.

Experts conclude the series discussing how to approach switching psoriasis treatments.

Experts discuss package warnings associated with bimekizumab and how they inform patients of them.

Experts discuss bimekizumab for the treatment of psoriasis highlighting is efficacy over other treatments.

This analysis highlighted several trends in search volume regarding eczema, including correlations with weather and climate.

The extent of stigma significantly differs based on disease visibility and severity among children with chronic skin disorders.

New phase 3b/4 trial data compared both drugs efficacy and safety profiles for eczema patients, looking at adults and adolescents.

A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Eblasakimab shows promising itch relief in dupilumab-experienced atopic dermatitis patients, with significant reductions in symptoms observed.

This presentation at ACP Internal Medicine 2024 covered key skills Colven believes internists should know for identification of dermatologic conditions.

Experts emphasize the importance of collaboration with infectious disease specialists for patients with tuberculosis, while highlighting the low reactivation rates in newer agents.

These data represent the largest single-center, long-term study on booster vaccines at a public hospital’s dermatology department in Japan.

This analysis compared the efficacy of a 5 mg daily dose of oral minoxidil to topical minoxidil, 5%, among male alopecia patients.

Experts highlight how a history of cancer may impact psoriasis treatment decisions while touching on the safety profiles of newer IL agents.

Experts discuss common comorbidities for patients with plaque psoriasis and how they can impact treatment decisions.

Dermatology physician assistants review the short- and long-term clinical trial data on deucravacitinib.

Dermatology physician assistants review the laboratory and monitoring requirements for TYK2 inhibitors deucravacitinib.

These data highlight the frequency of adverse events with narrow-band UVB phototherapy and concomitant therapy.

This analysis was conducted to address the fact that, while there are various acne specific instruments to assess quality of life domains, none exist to focus on all of the domains.

This study’s investigators point to the necessity of adapting an antibiotic stewardship program for acne treatment, with evaluation being done in dermatology practices to assess performance.

In these data, investigators had investigated the international differences in topical AK medication implementation, including links to countries’ different economic statuses.